This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Q2 revenue up 34%, profit turns positive; results restated for merger
LYKALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.4 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Unaudited Q2 FY27 results show standalone operating revenue up 34% to Rs 4,419.95 lakh from Rs 3,297.03 lakh. Profit reached Rs 210.03 lakh versus a Rs 362.07 lakh loss. H1 revenue rose 39% to Rs 8,650.89 lakh, with profit of Rs 341.53 lakh versus a Rs 280.99 lakh loss. The auditor gave an unqualified conclusion. Lyka Export merger caused prior-period restatement. A postal ballot seeks approval for the director reappointment.
Shareholders may see revenue growth and the profit turnaround positively, but restated merger figures and exceptional items complicate comparisons.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹44.20 Cr | ₹36.66 Cr | +20.6% |
| Operating profit | ₹0.45 Cr | −₹5.48 Cr | turned positive |
| Profit after tax | ₹1.27 Cr | −₹3.21 Cr | turned positive |
| EBITDA margin | 8.0% | -6.9% | +14.9 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.